Nonalcoholic Steatohepatitis Therapeutics And Diagnostics Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

NASH represents a progressive liver disease affecting an estimated 5-8% of the global adult population, often co-morbid with metabolic syndrome, obesity, and type 2 diabetes. The market encompasses pharmacological therapies spanning multiple drug classes, alongside diagnostic products and companion tools used in screening, staging, and monitoring disease progression. After years of limited treatment options, the sector is entering a commercially transformative phase driven by late-stage pipeline candidates, with market valuations reflecting strong investor and industry expectations around eventual approvals.

• •Market size estimates for the broader NASH treatment space range from roughly $5.5 billion to over $10 billion depending on year, scope (therapeutics only vs. therapeutics and diagnostics combined), and methodology
• •The field has experienced multiple high-profile late-stage clinical trial setbacks, creating a volatile but high-stakes environment for drug developers
• •Diagnostics play a critical role given the gold-standard liver biopsy is invasive; non-invasive biomarker and imaging-based diagnostic tools represent a growing sub-market

Rising global prevalence of obesity and type 2 diabetes constitutes the primary epidemiological driver, expanding the addressable patient pool for NASH therapies. A substantial unmet medical need exists, as treatment options have historically been limited to lifestyle interventions, creating strong incentive for pharmaceutical investment. Advancing late-stage and Phase III clinical trial data from multiple candidate agents has energized market expectations and attracted significant capital into the space.

• •Estimated 400-700 million people worldwide suffer from NAFLD, with 15-30% of those progressing to NASH, creating one of the largest addressable patient populations in liver disease
• •No widely approved disease-modifying pharmacological therapy existed until very recently, leaving the market largely untapped at the commercial level
• •Advances in non-invasive diagnostic technologies, including serum biomarkers and imaging-based fibrosis assessment tools, are lowering screening barriers and expanding the treatable population

The market is commonly segmented by drug class, including FXR agonists, PPAR agonists, ASK1 inhibitors, ACC inhibitors, and GLP-1 receptor agonists, as well as by diagnostic modality such as serum-based biomarker tests, elastography imaging devices, and genetic risk profiling tools. Regional distribution is heavily weighted toward North America, driven by high NASH prevalence, advanced healthcare infrastructure, and early regulatory pathways; Europe and the Asia-Pacific region represent the next-largest markets with growing adoption.

• •North America accounts for the largest regional market share, supported by high metabolic disease burden, favorable clinical research environments, and established reimbursement frameworks
• •Europe represents the second-largest region, with increasing diagnostic screening programs and growing clinical trial activity across Western and Northern European markets
• •Asia-Pacific is the fastest-growing regional segment, propelled by rising obesity rates, improving healthcare access, and expanding clinical development footprints by global pharmaceutical developers

Who are the notable companies in the industry?

The NASH therapeutics and diagnostics market features a competitively fragmented landscape, with key players strategically positioned across therapeutic development and diagnostic innovation. Genfit and Intercept Pharmaceuticals are advancing novel therapeutics, with Intercept commercializing resmetirom, the first FDA-approved NASH drug, while Genfit pursues elafibranor in late-stage trials. Madrigal Pharmaceuticals Inc. leads in targeted metabolic modulation, and Gilead Sciences and Novo Nordisk are leveraging their metabolic disease expertise to expand into NASH therapeutics pipelines. In diagnostics, GE Healthcare and Siemens Healthineers provide AI-enabled imaging solutions critical for non-invasive liver assessment, while Tawazun Health supports regional diagnostic infrastructure in the Middle East. These firms are integral to scaling diagnostic workflows in hospitals and specialized centers, where demand is accelerating. The market’s growth is further fueled by the integration of blood-based biomarkers and fast-track regulatory pathways, intensifying competition among biotech innovators and large pharma alike. While diagnostics currently dominate revenue (59.85% in 2025), the therapeutics segment is surging at a 19.11% CAGR, signaling a structural shift toward treatment-centric value creation.

• •The pipeline features a broad range of drug development approaches targeting multiple disease pathways simultaneously, including FXR, PPAR, ASK1, ACC, and GLP-1 receptor mechanisms, reflecting scientific uncertainty about optimal therapeutic targets
• •A significant share of clinical-stage development is being driven by biotechnology firms specializing in metabolic and liver disease, with larger pharmaceutical companies pursuing both internal programs and external licensing or acquisition transactions
• •Capacity and clinical trial activity is geographically concentrated in North America and Europe, though increasing late-stage trial enrollment is occurring in Asia-Pacific markets with large, underdiagnosed patient populations

What are the recent trends and outlook?

A prominent trend in the market is the increasing application of non-invasive diagnostic endpoints in clinical trials, which is accelerating development timelines and potentially lowering the cost of future drug registration programs. Combination therapy strategies are emerging as a leading approach, with many developers exploring multi-drug regimens targeting complementary metabolic pathways. The market is projected to sustain high double-digit growth through the early 2030s, contingent upon continued successful advancement of late-stage pipeline candidates and the establishment of reimbursement pathways for novel NASH therapies.

• •GLP-1 receptor agonists, originally developed for diabetes and obesity, are generating significant clinical interest in NASH given their demonstrated fibrosis and steatosis improvement, potentially reshaping the competitive landscape
• •Accelerated and breakthrough therapy designations from regulatory agencies in key markets are increasingly sought for NASH candidates, reflecting the high unmet need designation and potentially shortening development timelines
• •The long-term market outlook hinges on achieving durable, long-term patient outcomes; therapies demonstrating meaningful fibrosis regression and liver-related event reduction are expected to command premium pricing and strong commercial uptake